8-K: VolitionRx Q3 2025: Revenue Up, New Human Diagnostic Deals

VolitionRx Limited announced its third quarter 2025 financial results, reporting a 32% revenue increase and securing two significant human diagnostics agreements.

Summary

• Revenue for the third quarter of 2025 was $0.6 million, representing a 32% growth over the same quarter last year.
• Operating expenses for the quarter were down 10% year-on-year, and down 18% for the first three quarters of 2025.
• Net loss was down 8% for the quarter and down 20% for the first three quarters compared to the prior year.
• Net cash used in operating activities was $3.6 million for the quarter, a 33% reduction over the same period prior year.
• Subsequent to quarter end, the company received net proceeds of approximately $6.1 million from a confidentially-marketed public offering, including partial exercise of the underwriters' overallotment option.
• Signed a Research License and Exclusive Commercial Option Rights Agreement for Antiphospholipid Syndrome (APS) with Werfen.
• Entered into a Co-Marketing and Services Agreement with Hologic, both multi-billion dollar companies and leaders in their fields.

Sentiment

Score: 8

Explanation: The company reported strong financial improvements with increased revenue, reduced expenses and net loss, and decreased cash burn. Crucially, it secured two significant human diagnostics agreements with major industry players and successfully raised capital, indicating positive commercial and financial momentum.

Positives

• Revenue grew by 32% to $0.6 million in Q3 2025 compared to the prior year, indicating commercial traction.
• Operating expenses decreased by 10% year-over-year for the quarter and 18% for the first three quarters, demonstrating improved cost management.
• Net loss improved by 8% for the quarter and 20% for the first three quarters, signaling progress towards profitability.
• Net cash used in operating activities reduced by 33% to $3.6 million for the quarter, improving cash flow efficiency.
• Secured two significant human diagnostics agreements with multi-billion dollar industry leaders, Werfen and Hologic, for the Nu.Q platform.
• Engaged in discussions with approximately 10 of the world's leading diagnostic and liquid biopsy companies for further licensing deals.
• Anticipates peer-reviewed publications across all technology pillars, including the groundbreaking Capture-Seq technology, in coming quarters.
• Successfully raised approximately $6.1 million in net proceeds from a public offering subsequent to quarter end, strengthening the balance sheet.

Negatives

• The company continues to report a net loss, although it has decreased.
• Still utilized $3.6 million in net cash from operating activities for the quarter.

Risks

• Failure to develop and commercialize diagnostic, prognostic, or disease monitoring products.
• Inability to obtain necessary regulatory clearances or approvals to distribute and market future products.
• Lack of market acceptance for products in the development pipeline or any other diagnostic, prognostic, or disease monitoring products.
• Failure to secure adequate intellectual property protection.
• Fierce competition and potential obsolescence of intended products due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change.
• Downturns in domestic and foreign economies.

Future Outlook

VolitionRx anticipates securing further human licensing deals with a range of large companies, mirroring its successful strategy in the veterinary market, with potential for upfront and milestone payments, and future recurring revenue. The company expects peer-reviewed publications across all its technology pillars, including Capture-Seq, in the coming quarters, supporting the broad applicability of its Nu.Q technology in critical areas like cancer and sepsis.

Management Comments

• "2025 efforts for Volition focused on commercializing our groundbreaking Nu.Q platform in the human diagnostics market and we were excited this quarter to sign not one, but two human agreements: a Research License and Exclusive Commercial Option Rights Agreement for Antiphospholipid Syndrome ("APS") with Werfen and a Co-Marketing and Services Agreement with Hologic."
• "We are in discussions with around 10 of the worlds leading diagnostic and liquid biopsy companies and are at various stages of the process across our different pillars, ranging from due diligence to tech transfer, to evaluation of clinical samples, to term sheet and contract negotiation."
• "Our goal is to secure a range of licensing agreements in the human diagnostics space, mirroring our successful strategy in the veterinary market, and anticipate, similar to the veterinary market, diverse deal structures, with potential for up front and milestone payments, and future recurring revenue."
• "We believe we have developed a unique and widely applicable platform that will contribute significantly to oncology and NETosis detection and monitoring for decades to come, and for hundreds of millions of people and animals worldwide."

Industry Context

VolitionRx's focus on epigenetics and liquid biopsy technologies aligns with a significant trend in the diagnostics industry towards less invasive, earlier detection methods for complex diseases like cancer and sepsis. The strategic partnerships with established multi-billion dollar companies like Werfen (specializing in in-vitro diagnostics) and Hologic (a leader in women's health and diagnostics) validate the potential of Volition's Nu.Q platform and position it to compete in a rapidly expanding market driven by advancements in genomic and proteomic analysis.

Comparison to Industry Standards

• The signing of two significant human diagnostics agreements with established industry leaders like Werfen and Hologic suggests a positive validation of Volition's Nu.Q platform, potentially positioning it favorably against smaller, less validated competitors in the liquid biopsy space.
• The reported 32% revenue growth, while from a low base ($0.6 million), indicates commercial traction, which is crucial for early-stage diagnostic companies often characterized by high R&D costs and delayed revenue generation.
• The reduction in operating expenses (down 10% for the quarter) and net cash used in operating activities (down 33%) demonstrates improved financial efficiency, which is a positive sign in a capital-intensive industry where many emerging diagnostic companies struggle with cash burn.
• The ongoing discussions with approximately 10 leading diagnostic and liquid biopsy companies for further licensing deals indicate a strong pipeline of potential partnerships, comparable to the strategic approaches seen in successful biotech firms that leverage licensing to accelerate market penetration.

Stakeholder Impact

• Shareholders: Positive impact due to revenue growth, reduced losses, new strategic partnerships, and successful capital raise, potentially increasing shareholder value and confidence.
• Customers (future): Potential for improved disease detection and monitoring through the commercialization of Nu.Q platform tests.
• Employees: Continued focus on commercialization and R&D may lead to stability and growth opportunities.
• Partners (Werfen, Hologic): Strengthened collaboration through new agreements.

Next Steps

• Host a conference call on November 14, 2025, to discuss Q3 2025 financial and operational results and upcoming milestones.
• Continue discussions with approximately 10 leading diagnostic and liquid biopsy companies for further human licensing deals.
• Anticipate further human licensing deals to be completed.
• Anticipate peer-reviewed publications across all technology pillars, including Capture-Seq, in the coming quarters.

Key Dates

Recommendation

The company demonstrated significant progress in Q3 2025 with strong revenue growth, improved financial efficiency (reduced operating expenses and net loss, lower cash burn), and, most importantly, secured two pivotal human diagnostics licensing agreements with multi-billion dollar industry leaders. The successful capital raise further strengthens its financial position. These developments indicate strong commercial validation and execution of its strategy, suggesting a positive trajectory for future growth and market penetration in the high-potential epigenetics and liquid biopsy space.

Keywords

VolitionRx, VNRX, Epigenetics, Nu.Q platform, Human Diagnostics, Cancer Detection, Sepsis, Liquid Biopsy, Financial Results, Q3 2025, Licensing Agreements, Werfen, Hologic, Antiphospholipid Syndrome, APS, NETosis, Biomarker, Epigenetic Drug Development, Capture-Seq